Spinocerebellar Ataxia Genetic Test: CAG Repeat Expansions and Results

A spinocerebellar ataxia CAG repeat test measures repeated CAG DNA units in specific genes associated with inherited ataxia. Common targets include ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, and TBP, which cause SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17. The test is not a single universal “ataxia gene” screen: every locus has its own normal, intermediate, reduced-penetrance, and pathogenic ranges. Repeat interruptions and laboratory method can change interpretation even when the reported count looks similar. A pathogenic expansion can confirm the molecular diagnosis in a symptomatic person and may allow predictive testing for adult relatives. It still cannot provide an exact age of onset, rate of progression, or symptom list. A negative CAG panel also does not exclude hereditary ataxia because many important ataxias are caused by other repeat motifs, recessive expansions, sequence variants, copy-number changes, mitochondrial variants, or acquired conditions.

• CAG repeat thresholds are gene-specific; one repeat number cannot be interpreted across all SCA types.
• Standard exome sequencing may miss clinically important repeat expansions unless a validated expansion analysis is included.
• Interruptions within a repeat can affect stability, penetrance, and the accuracy of simple sizing.
• Longer pathogenic repeats often correlate with earlier onset, but the relationship is probabilistic rather than exact.
• Predictive testing should usually begin only after the familial expansion is confirmed in an affected relative.

Table of Contents

• What a CAG Repeat Expansion Test Actually Detects
• Common CAG Expansion Ataxias and Their Result Ranges
• Why the Testing Method Matters
• How to Interpret Normal, Intermediate, and Pathogenic Results
• Repeat Instability, Anticipation, and Parent of Origin
• Diagnostic, Predictive, and Reproductive Testing
• What a Negative CAG Panel Does Not Rule Out
• Care Planning After a Positive Result

What a CAG Repeat Expansion Test Actually Detects

CAG is a three-letter DNA sequence that codes for the amino acid glutamine when it lies in a protein-coding region. In several dominant ataxias, the gene contains a stretch of repeated CAG units. When the stretch becomes long enough, the resulting protein carries an expanded polyglutamine tract that disrupts nerve-cell function. Different genes affect different networks, so the clinical picture can include much more than imbalance.

Ataxia means impaired coordination. It may appear as an unsteady gait, slurred speech, inaccurate hand movements, tremor, abnormal eye movements, or difficulty swallowing. Depending on the SCA type, a person may also develop neuropathy, stiffness, dystonia, parkinsonism, weakness, retinal degeneration, seizures, cognitive change, or psychiatric symptoms. Brain MRI may show cerebellar or brainstem atrophy, but imaging cannot identify the repeat expansion by itself.

A targeted repeat test asks whether one or both alleles at a named locus fall into a defined size and sequence category. Most CAG SCAs are autosomal dominant: one pathogenic expanded allele is sufficient to create substantial disease risk, and each child of an affected person has a 50% chance of inheriting it. The laboratory normally reports two allele sizes, such as 22 and 67 repeats, unless one allele cannot be sized or the method reports only that an expansion is present.

The result is locus-specific. Sixty CAG repeats would be far above the pathogenic threshold for SCA6, within the pathogenic range for SCA3, and interpreted differently in TBP because SCA17 contains a mixed CAG/CAA tract. The report must identify the gene, transcript or reference sequence, repeat motif, counting convention, and classification.

CAG testing may be ordered as a single-gene assay when a known family expansion or distinctive phenotype points to one subtype. More often, laboratories offer an ataxia repeat panel that tests several common expansions together. Panel content varies with ancestry, geography, phenotype, and technology. The name “SCA panel” does not guarantee that every known SCA, every repeat motif, or sequence-based ataxia gene is included.

A repeat expansion test differs from routine sequencing. Standard sequencing is designed to read varied DNA letters, while tandem repeats create alignment and amplification problems. An order for whole-exome sequencing may analyze the coding sequence around an ataxia gene but still fail to measure its expanded repeat accurately. The laboratory’s explicit repeat-expansion methods matter more than the broad test name.

Common CAG Expansion Ataxias and Their Result Ranges

The following ranges are representative clinical categories, not a substitute for the testing laboratory’s current interpretation. Borderline alleles require attention to interruptions, family segregation, ancestry, symptoms, and the assay’s counting method.

Condition and gene	Representative repeat categories	Features that may guide testing
SCA1, ATXN1	Usually normal through 35; uninterrupted 36–38 alleles may be mutable; uninterrupted alleles of 39 or more are generally pathogenic. CAT interruptions can change classification.	Progressive ataxia, dysarthria, pyramidal signs, neuropathy, and bulbar dysfunction.
SCA2, ATXN2	Usually normal through 31; 32 is uncertain; 33–34 has reduced penetrance; more than 34 is generally full penetrance. CAA interruptions affect stability.	Slow saccades, neuropathy, tremor, parkinsonism, and sometimes cognitive change.
SCA3, ATXN3	12–44 is generally normal; approximately 45–59 is an intermediate or variably expressive zone; about 60 or more is usually full penetrance.	Ataxia with variable dystonia, spasticity, neuropathy, weakness, eye-movement abnormalities, or parkinsonism.
SCA6, CACNA1A	18 or fewer is normal; 19 is of uncertain or mutable significance; 20–33 is pathogenic.	Often later-onset, slowly progressive, relatively pure cerebellar ataxia with nystagmus.
SCA7, ATXN7	27 or fewer is generally normal; 28–33 is mutable normal; 34–36 has reduced penetrance; 37 or more is generally full penetrance.	Ataxia plus progressive retinal degeneration and visual loss; large expansions may cause early severe disease.
SCA17, TBP	Typically 40 or fewer is normal; 41–48 has reduced or variable penetrance; 49 or more is generally pathogenic. The tract contains both CAG and CAA units.	Ataxia with cognitive, psychiatric, choreic, dystonic, or parkinsonian features.
DRPLA, ATN1	Usually 35 or fewer is normal; 36–47 may have reduced or uncertain penetrance; 48 or more is pathogenic.	Ataxia, chorea, dementia, myoclonus, and epilepsy; juvenile disease is often associated with larger repeats.

DRPLA is not usually numbered as an SCA, but it is often included in CAG ataxia panels because the phenotype overlaps. The panel may also include androgen receptor testing for spinal and bulbar muscular atrophy when weakness, fasciculations, and endocrine features suggest that diagnosis.

Several cautions apply to the table. First, threshold boundaries are not equally certain. SCA3 has a poorly defined transition between intermediate and fully penetrant alleles. Second, a pure CAG length and a repeat interrupted by CAT or CAA units may encode or transmit differently. Third, laboratories may count the uninterrupted CAG segment, the total glutamine-encoding tract, or a combined repeat block according to gene-specific conventions.

A borderline number should never be interpreted by searching only for “normal range” online. The report should explain whether the allele is normal, mutable normal, intermediate, reduced penetrance, or pathogenic and cite the evidence used. When the report is unclear, the laboratory director or a neurogenetics professional should be asked how the sequence was counted and whether interruptions were characterized.

Why the Testing Method Matters

Repeat expansions challenge ordinary DNA testing because the expanded allele may be much longer than a standard PCR product or sequencing read. A complete method often combines detection and sizing rather than relying on one assay.

Conventional PCR with capillary electrophoresis amplifies the repeat region and estimates fragment size. It can accurately size many normal and modestly expanded alleles. However, a very large allele may fail to amplify. The test may then show one apparently normal allele and look homozygous even though an undetected expansion is present. Allele dropout is a major reason a single peak cannot automatically be called negative.

Repeat-primed PCR uses primers that bind within the repeat and produces a characteristic stutter pattern when an expansion is present. It is effective for detecting many expanded alleles even when exact sizing is difficult. The method may confirm “expansion detected” without providing a reliable repeat count, especially for very long or complex tracts.

Long-range PCR, Southern blotting, or other expanded-repeat analysis can estimate large allele sizes that conventional PCR cannot resolve. Southern blotting requires more DNA and is labor-intensive but remains useful for selected large expansions. Laboratories may use orthogonal confirmation when a result lies near a threshold, appears homozygous, or will be used for predictive or prenatal testing.

Short-read genome sequencing can screen for a growing number of repeat expansions when validated algorithms and manual review are used. Its performance varies by locus, motif, expansion size, and pipeline. A “genome negative” report should list which repeats were assessed and with what sensitivity. Long-read sequencing can span expanded alleles, identify interruptions, phase repeats with nearby variants, and characterize complex structures. It is increasingly useful but is not yet a uniformly available replacement for targeted clinical assays.

Sample quality also matters. Blood is standard, but somatic mosaicism can produce slightly different repeat lengths across tissues and cells. Laboratories often report the predominant blood allele rather than every minor length. Prenatal samples need maternal-cell-contamination studies, and a familial assay should be validated for the exact expansion before pregnancy testing.

Before ordering, ask whether the panel includes detection of large alleles, sizing, interruption analysis, and confirmation. An ataxia panel that performs only conventional PCR may be adequate for some loci but incomplete for others. A sequence-based multigene panel should state separately whether repeat expansion analysis is included.

How to Interpret Normal, Intermediate, and Pathogenic Results

A normal result means both measured alleles fall within the laboratory’s normal range for that gene and no expansion was detected by the stated method. It substantially reduces the likelihood of the tested SCA subtype. It does not exclude another SCA gene, a non-CAG expansion, a sequence variant in the same gene, or an acquired cause of ataxia.

A mutable-normal or intermediate allele usually does not establish the person’s symptoms as that SCA. Its importance may be reproductive: the repeat can be unstable and expand into a disease-associated range in a child. In some genes, intermediate alleles have been linked to subtle or different phenotypes, but those associations should not be generalized. The family history and exact repeat structure are essential.

A reduced-penetrance result means the allele is associated with disease but not everyone who carries it develops symptoms during a normal lifetime. Onset may be late, and an apparently unaffected older parent can transmit the allele. Reduced penetrance is not the same as a variant of uncertain significance. The disease association is established, but the probability and timing of expression are incomplete.

A full-penetrance pathogenic expansion strongly supports the corresponding diagnosis in a symptomatic person. In an asymptomatic adult, it indicates a high lifetime risk for the specific disorder, but it still cannot predict the exact onset date. Repeat length often explains part of age-at-onset variation, while other genes, environment, somatic expansion, and chance contribute substantially.

The count itself has measurement uncertainty. Many laboratories report an estimated repeat number with a tolerance of one or more units. That difference is usually unimportant far from a threshold but may alter classification at a boundary. A borderline result may warrant repeat testing, sequencing of interruptions, family segregation, or confirmation by another method.

A result should be reviewed for:

• the gene and SCA subtype;
• both allele sizes and any stated measurement range;
• whether the repeat is pure or interrupted;
• the classification and penetrance category;
• the method used to detect large alleles;
• whether the result fits the symptoms and family history;
• recommendations for confirmation, relatives, or reanalysis.

A pathogenic expansion is not interchangeable with a small pathogenic sequence variant. Repeat disorders have unique instability and counseling issues. Likewise, an ordinary VUS classification framework may not fully describe an allele whose risk depends on repeat size, interruptions, and penetrance.

Repeat Instability, Anticipation, and Parent of Origin

CAG repeats can change length when passed from parent to child. Expansion is more common than contraction for several SCAs. When a child inherits a longer pathogenic repeat and develops symptoms earlier or more severely than the parent, the pattern is called anticipation.

Anticipation is not identical across disorders. SCA7 is especially unstable, and large increases are more often seen with paternal transmission. A child may develop visual loss and neurologic symptoms years before a mildly affected parent is recognized. SCA1, SCA2, and SCA3 also show instability and anticipation, but the size and parent-of-origin effects vary. SCA6 expansions are relatively stable, and classic anticipation is not generally observed.

Repeat interruptions can stabilize an allele. In SCA1, CAT interruptions within the CAG tract can distinguish a nonpathogenic or less penetrant allele from a pathogenic uninterrupted allele with a similar total length. In SCA2, CAA interruptions still encode glutamine but may reduce meiotic instability. TBP naturally contains a mixed CAG/CAA tract, so the total polyglutamine-encoding length and internal structure must be interpreted according to SCA17-specific rules.

A larger repeat often correlates with earlier onset, but this is not a clock. Two relatives with the same measured repeat may develop symptoms years apart. Blood repeat length may not capture ongoing somatic expansion in vulnerable brain regions. Clinical factors and genetic modifiers add variation that a diagnostic report cannot calculate for one person.

For family counseling, the important questions are whether the allele is unstable, whether parent of origin affects expansion risk, and whether the current allele lies near a threshold. A mutable-normal allele may carry little immediate health risk to the tested adult but meaningful risk of expansion in descendants. A full expansion gives each child a 50% chance of inheriting the allele in an autosomal dominant SCA, but the child’s final repeat length and phenotype cannot be promised in advance.

Families should avoid comparing repeat counts across genes or assuming that every increase of five repeats has the same effect. A five-repeat change is enormous for SCA6, modest for some SCA3 alleles, and interpreted under a different counting system in SCA17.

Diagnostic, Predictive, and Reproductive Testing

Diagnostic testing is performed in a person with symptoms. The neurologic examination, onset pattern, MRI, eye findings, nerve studies, ancestry, and family history help select the panel. A negative family history does not exclude dominant SCA because of late onset, reduced penetrance, early death, adoption, small families, or a newly expanded allele.

Predictive testing is performed in an asymptomatic person at risk because a parent or other close relative has a confirmed expansion. The safest approach tests the exact familial gene and method rather than ordering a broad panel. Pretest counseling should cover the possible result, inability to predict onset, emotional impact, family relationships, privacy and insurance rules in the person’s country, employment concerns, and plans for support after disclosure.

Predictive testing for adult-onset SCA is generally deferred in asymptomatic minors because there is usually no childhood intervention that changes outcome, and the result removes the future adult’s choice. Testing a child who has neurologic symptoms is diagnostic, not predictive, and may be appropriate. Early-onset disorders such as large SCA7 or DRPLA expansions require individualized pediatric genetics and neurology input.

A person at 50% risk may choose testing, decline testing, or postpone it. Each choice is valid. Some adults test for family planning or life decisions; others prefer uncertainty. Testing should not be ordered by a relative, employer, or insurer without the person’s informed consent.

Once a familial pathogenic expansion is known, reproductive options may include prenatal diagnosis through chorionic villus sampling or amniocentesis, preimplantation genetic testing with in vitro fertilization, donor gametes, adoption, or pregnancy without genetic testing. Prenatal testing determines whether the familial expansion is present and may estimate size, but repeat instability and phenotype variability limit prognostic precision.

Some programs offer exclusion-based prenatal or preimplantation testing for a person who does not want to learn their own predictive status. This approach uses linked family markers to avoid knowingly transferring the at-risk chromosome, but it is technically and ethically complex and not available everywhere.

Testing should begin with an affected relative whenever possible. A negative result in an unaffected person is only truly reassuring if the family’s causal expansion is already known. Otherwise, the person may test negative for the wrong genes while the family’s actual cause remains unidentified.

What a Negative CAG Panel Does Not Rule Out

A negative common CAG panel rules out only the expansions and allele sizes that the assay could reliably detect. Many frequent or treatable causes of ataxia lie outside that scope.

Other repeat-expansion disorders include biallelic RFC1 expansions associated with CANVAS and late-onset ataxia, FGF14 GAA expansions causing SCA27B, FXN GAA expansions causing Friedreich ataxia, NOP56 expansions causing SCA36, ATN10 expansions causing SCA10, DAB1 repeat insertions causing SCA37, ZFHX3 GGC expansions causing SCA4, and ATXN8OS expansions associated with SCA8. These motifs require locus-specific validation and may not appear on a “CAG panel.”

Sequence variants and copy-number changes in dozens of genes can also cause dominant, recessive, X-linked, or mitochondrial ataxia. Examples include CACNA1A sequence variants, SETX, SPG7, SYNE1, PNKP, COQ8A, and mitochondrial genes. A broader neurologic genetic panel, chromosomal testing, exome, genome, or mitochondrial testing may be appropriate after repeat analysis, depending on phenotype and age.

The clinical workup must also consider acquired and treatable causes. Medication toxicity, alcohol exposure, vitamin E or thiamine deficiency, thyroid disease, gluten-related or other immune ataxia, paraneoplastic disease, infection, stroke, tumor, multiple-system atrophy, and structural lesions can mimic inherited disease. Rapid progression, systemic symptoms, cancer history, or an inflammatory course should broaden evaluation urgently.

When the result is negative, review the report rather than ordering the identical panel again. Ask which loci were included, whether repeat-primed PCR was used, whether apparently homozygous alleles were checked for dropout, whether newer expansions such as FGF14 and RFC1 were assessed, and whether raw genome data can be reanalyzed. Geographic ancestry can guide additions but should not be used to exclude a test when the phenotype fits.

A test performed years ago may be incomplete today. New repeat expansions continue to be discovered, and genome pipelines are improving. Periodic reanalysis or referral to a specialized ataxia clinic can convert an unsolved result into a diagnosis without assuming the original symptoms were nongenetic.

Care Planning After a Positive Result

A positive expansion result should lead to subtype-specific evaluation. The first visit should confirm that the phenotype matches the gene, establish baseline function, review medications and fall risk, and identify complications that may be preventable or treatable.

Physical and occupational therapy can support balance, strength, transfers, home safety, mobility aids, and energy conservation. Speech-language assessment addresses dysarthria, communication devices, and swallowing safety. Nutrition, aspiration risk, sleep, mood, cognition, driving, employment, and caregiver needs should be reviewed over time. Exercise is usually encouraged within safe limits, but a therapist familiar with neurologic disease can tailor the plan.

Surveillance varies by subtype. SCA7 requires ophthalmologic assessment because retinal degeneration may drive disability. SCA1 and some other SCAs may involve swallowing and respiratory complications. SCA2 and SCA3 can include neuropathy, parkinsonism, dystonia, restless legs, or autonomic symptoms. SCA17 and DRPLA may require early attention to cognition, psychiatric symptoms, chorea, seizures, or behavior. Management should follow the person’s actual findings rather than a checklist alone.

There is no single approved treatment that reverses all CAG-expansion SCAs. Symptom-directed medication may help tremor, spasticity, dystonia, parkinsonism, depression, sleep disturbance, or seizures, but adverse effects can worsen balance or swallowing. Clinical trials are investigating gene-silencing, RNA-targeted, protein-lowering, and neuroprotective strategies. Eligibility may depend on the exact gene, repeat result, disease stage, and country.

Relatives should receive a copy of the exact report and a family letter explaining how to seek counseling, not pressure to test. The tested person should keep the allele sizes, method, laboratory, and date because repeat counts from different assays may not be directly interchangeable.

A molecular diagnosis can end years of uncertainty, connect a family with subtype-specific resources, and clarify who is eligible for predictive testing. Its limits are equally important: it cannot define the person’s value, guarantee a timeline, or replace ongoing neurologic care. The best plan uses the genetic result as one precise piece of a broader clinical picture.

References

• Hereditary Ataxia Overview, GeneReviews (updated 2025).
• Repeat Expansion Disorders (2024).
• A Prospective Trial Comparing Targeted Long-Read and Short-Read Genome Sequencing for Cerebellar Ataxia (2025).
• Spinocerebellar Ataxia Type 1, GeneReviews (updated 2023).
• Spinocerebellar Ataxia Type 17, GeneReviews (updated 2022).
• Spinocerebellar Ataxia Type 3, GeneReviews (updated 2020).

Disclaimer

This article provides general education and is not a diagnosis, predictive-testing protocol, or individualized medical advice. CAG repeat results should be interpreted by a qualified neurogenetics clinician or genetic counselor using the exact gene, assay, repeat structure, symptoms, and family history. Seek urgent care for sudden ataxia, new severe weakness, choking, prolonged seizure, or another medical emergency.